Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan, China.
Lipids Health Dis. 2022 Mar 2;21(1):27. doi: 10.1186/s12944-022-01637-7.
Chemerin is a brand-new adipokine that has been linked to both inflammation and metabolic dysfunction. Even though a rising number of studies have connected chemerin to metabolic-associated fatty liver disease (MAFLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), this association has been controversial.
A comprehensive literature search was undertaken up to February 1, 2022, in the PubMed, Embase, Web of Science, CNKI, WANFANG, and CBM library databases. Circulating chemerin levels were obtained and summarized using the standardized mean difference (SMD) and 95% confidence interval (CI). Subgroup and meta-regression analyses were conducted to examine the possibility of heterogeneity.
A total of 17 studies involving 2580 participants (1584 MAFLD patients and 996 controls) evaluated circulating chemerin levels in patients with MAFLD. The present study showed that higher chemerin levels were found in patients with MAFLD (SMD: 1.32; 95% CI: 0.29, 2.35) and nonalcoholic fatty liver (NAFL) (SMD: 0.75; 95% CI: 0.01, 1.50) compared to controls. However, circulating chemerin levels did not differ significantly in the following comparisons: nonalcoholic steatohepatitis (NASH) patients and controls (SMD: 0.75; 95% CI: -0.52, 2.03); NASH patients and NAFL patients (SMD: 0.16; 95% CI: -0.39, 0.70); moderate to severe steatosis and mild steatosis (SMD: 0.55; 95% CI: -0.59, 1.69); present liver fibrosis and absent liver fibrosis (SMD: 0.66; 95% CI: -0.42, 1.74); present lobular inflammation and absent lobular inflammation (SMD: 0.45; 95% CI: -0.53, 1.42); and present portal inflammation and absent portal inflammation (SMD: 1.92; 95% CI: -0.85, 4.69).
Chemerin levels were considerably greater in patients with MAFLD than in controls, despite the fact that they were not significantly linked to different liver tissue lesions of MAFLD. In different subtypes of MAFLD, in comparison to healthy controls, the chemerin levels of NAFL patients were higher, whereas, there was no obvious difference in chemerin levels between NASH patients and controls. It is possible that chemerin will be used as a biomarker in the future to track the development and progression of MAFLD.
趋化素是一种全新的脂肪因子，与炎症和代谢功能障碍均有关联。尽管越来越多的研究表明趋化素与代谢相关的脂肪性肝病（MAFLD），以前称为非酒精性脂肪性肝病（NAFLD）有关，但这种关联一直存在争议。
截至 2022 年 2 月 1 日，我们在 PubMed、Embase、Web of Science、CNKI、Wanfang 和 CBM 数据库中进行了全面的文献检索。使用标准化均数差（SMD）和 95%置信区间（CI）汇总了循环趋化素水平。进行亚组和荟萃回归分析以检查异质性的可能性。
共纳入了 17 项研究，涉及 2580 名参与者（1584 名 MAFLD 患者和 996 名对照），评估了 MAFLD 患者的循环趋化素水平。本研究表明，MAFLD 患者（SMD：1.32；95%CI：0.29，2.35）和非酒精性脂肪肝（NAFL）患者（SMD：0.75；95%CI：0.01，1.50）的循环趋化素水平较高。然而，以下比较中循环趋化素水平没有显著差异：非酒精性脂肪性肝炎（NASH）患者和对照组（SMD：0.75；95%CI：-0.52，2.03）；NASH 患者和 NAFL 患者（SMD：0.16；95%CI：-0.39，0.70）；中重度脂肪变性和轻度脂肪变性（SMD：0.55；95%CI：-0.59，1.69）；存在肝纤维化和无肝纤维化（SMD：0.66；95%CI：-0.42，1.74）；存在肝小叶炎症和无肝小叶炎症（SMD：0.45；95%CI：-0.53，1.42）；存在门脉炎症和无门脉炎症（SMD：1.92；95%CI：-0.85，4.69）。
尽管趋化素与 MAFLD 的不同肝组织病变并无明显关联，但 MAFLD 患者的趋化素水平明显高于对照组。与健康对照组相比，NAFL 患者的趋化素水平较高，而 NASH 患者与对照组之间的趋化素水平没有明显差异。趋化素将来可能被用作 MAFLD 发展和进展的生物标志物。
